SCHEMBL14798583

SCHEMBL14798583

Nc1ccc(CNS(=O)(=O)NC(=O)O)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ ADRA2B P18089 1/20 0.43
▸ KMT2A Q03164 3/20 0.42
▸ AKR1B1 P15121 1/20 0.41
▸ MEN1 O00255 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ EPHX2 P34913 3/20 0.35
▸ NR1H4 Q96RI1 2/20 0.35
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ FFAR1 O14842 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14797865 0.81 CA12 (0.55) LMNAADRA2BKMT2AAKR1B1EPHX2
SCHEMBL4338177 0.80 AKR1B1 (0.53) ADRA2BKMT2AAKR1B1MEN1EPHX2
SCHEMBL13194426 0.77 ADRA2B (0.49) LMNAADRA2BKMT2AAKR1B1EPHX2
SCHEMBL14798746 0.75 CA2 (0.49) KMT2AMEN1EPHX2CA1CA2
SCHEMBL19212130 0.70 AKR1B1 (0.44) ADRA2BAKR1B1FFAR1TRPV1
SCHEMBL2298577 0.70 AKR1B1 (0.43) ADRA2BKMT2AAKR1B1MEN1RECQL
Malonic Acid SCHEMBL3810427 0.69 AKR1B1 (0.43) ADRA2BAKR1B1
SCHEMBL27619224 0.68 ADRA2B (0.41) LMNAADRA2BAKR1B1RECQLCA1
SCHEMBL2993995 0.68 ADRA2B (0.56) ADRA2BAKR1B1GAA
SCHEMBL4611520 0.67 FFAR1 (0.56) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937092-B2 Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2015-01-20 — — US disclosed
EP-2760835-A1 ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2014-08-06 — — EP disclosed
WO-2013045447-A1 ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2013-04-04 — — WO disclosed
US-20130079377-A1 Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2013-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079377-A1 Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands TRPV1, TRPV3, TRPA1 LMNA 3998/4885ADRA2B 311/4885KMT2A 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback